Supply chain transparency and the availability of essential medicines
- PMID: 33953450
- PMCID: PMC8085627
- DOI: 10.2471/BLT.20.267724
Supply chain transparency and the availability of essential medicines
References
-
- Cogan D, Karrar K, Iyer JK. Shortages, stockouts and scarcity. The issues facing the security of antibiotic supply and the role for pharmaceutical companies. Amsterdam: Access to Medicine Foundation; 2018. Available from: https://accesstomedicinefoundation.org/media/atmf/Antibiotic-Shortages-S... [cited 2020 Nov 27].
-
- Antibiotic shortages: magnitude, causes and possible solutions. Meeting report. Norwegian Directorate of Health, Oslo, Norway, 10–11 December 2018. Geneva: World Health Organization; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/311288/WHO-MVP-EMP-IAU-... [cited 2020 Nov 27].
-
- Schondelmeyer SW, Seifert J, Margraf DJ, Mueller M, Williamson I, Dickson C, et al. COVID–19: the CIDRAP viewpoint. Part 6: Ensuring a resilient US prescription drug supply. Minneapolis: Center for Infectious Disease Research and Policy; 2020. Available from: https://www.cidrap.umn.edu/sites/default/files/public/downloads/cidrap-c... [cited 2020 Nov 27].
-
- Medicine shortages in the EU: causes and solutions. Brussels: News European Parliament; 2020. Available from: https://www.europarl.europa.eu/news/en/headlines/society/20200709STO8300... [cited 2020 Nov 27].
-
- China API market by drug type (branded drugs, generic drugs, others) by API synthesis (biotech API, synthetic chemical API, others) by type of manufacturing (contract manufacturing, and in-house API manufacturing) and forecast – 2026. Hyderabad: Optima Insights; 2019. Available from: https://www.optimainsights.org/reports/69-china-api-market [cited 2020 Nov 27].
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources